Encouraging appropriate use of proton pump inhibitors: existing initiatives and proposals for the future

References

• Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997;17(1):22–37.
   PubMed Web of Science ®Google Scholar
• Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–1860. doi: 10.1053/j.gastro.2008.05.021
   PubMed Web of Science ®Google Scholar
• Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998;56(3):307–335. doi: 10.2165/00003495-199856030-00002
   PubMed Web of Science ®Google Scholar
• Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD an overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009; 59(3):135–153. doi: 10.1016/j.phrs.2008.09.016
   PubMed Web of Science ®Google Scholar
• Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012;5(4):219–232. doi: 10.1177/1756283X12437358
   PubMed Web of Science ®Google Scholar
• Shanika LGT EF, Reynolds A, Pattison S, et al. Proton pump inhibitor use: systematic review of global trends and practices [published online ahead of print, 2023 Jul 7]. Eur J Clin Pharmacol. 2023;10.1007/s00228-023-03534–z. doi: 10.1007/s00228-023-03534-z
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela GS, Scalabrini P, et al. Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer. Digestion. 1987;37(2):103–109. doi: 10.1159/000199475
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela GS, Zentilin P, et al. Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther. 1998;12(12):1241–1247. doi: 10.1046/j.1365-2036.1998.00416.x
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Merki HS. Tolerance during dosing with H 2 -receptor antagonists. Scand J Gastroenterol Suppl. 1992;193(sup193):14–19. doi: 10.3109/00365529209096000
   PubMedGoogle Scholar
• Kantor ED, Rehm CD, Haas JS, et al. Trends in prescription Drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818–1831. doi: 10.1001/jama.2015.13766
   PubMed Web of Science ®Google Scholar
• Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3. doi: 10.1136/bmj.39406.449456.BE
   PubMed Web of Science ®Google Scholar
• Cammarota S, Bruzzese D, Sarnelli G, et al. Proton pump inhibitors prescribing following the introduction of generic drugs. Eur J Clin Invest. 2012;42(10):1068–1078. doi: 10.1111/j.1365-2362.2012.02696.x
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Fendrick AM. PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol. 2005;3(3):208–215. doi: 10.1016/S1542-3565(04)00717-7
   PubMed Web of Science ®Google Scholar
• Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1123–1134. doi: 10.1080/17512433.2018.1531703
   PubMed Web of Science ®Google Scholar
• Dipasquale V, Cicala G, Spina E, et al. A narrative review on efficacy and safety of proton pump inhibitors in children. Front Pharmacol. 2022 Feb 10;13: 839972. doi: 10.3389/fphar.2022.839972.
   PubMed Web of Science ®Google Scholar
• Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis. 2016;48(8):851–859. doi: 10.1016/j.dld.2016.05.018
   PubMedGoogle Scholar
• Corleto VD, Festa S, Di Giulio E, et al. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014;21(1):3–8. doi: 10.1097/MED.0000000000000031
   PubMedGoogle Scholar
• Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018; 16(6):800–808.e7. doi: 10.1016/j.cgh.2017.09.033
   PubMed Web of Science ®Google Scholar
• Savarino V, Marabotto E, Zentilin P, et al. Pharmacological management of gastro-esophageal reflux disease: an update of the state-of-the-art. Drug Des Devel Ther. 2021;15:1609–1621. doi: 10.2147/DDDT.S306371
   PubMed Web of Science ®Google Scholar
• Ladd AM, Panagopoulos G, Cohen J, et al. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347(6):446–451. doi: 10.1097/MAJ.0b013e31829f87d5
   PubMed Web of Science ®Google Scholar
• Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):66–68. doi: 10.1136/pgmj.2006.051151
   PubMed Web of Science ®Google Scholar
• Savarino V, Tosetti C, Benedetto E, et al. Appropriateness in prescribing PPIs: a position paper of the Italian society of Gastroenterology (SIGE) — study section “digestive diseases in primary care”. Dig Liver Dis. 2018;50(9):894–902. doi: 10.1016/j.dld.2018.07.004
   PubMedGoogle Scholar
• Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–1810. doi: 10.1053/gast.1997.v112.pm9178669
   PubMed Web of Science ®Google Scholar
• van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2006;(3):CD002095.
   PubMed Web of Science ®Google Scholar
• Fox M, Gyawali CP. Dietary factors involved in GERD management. Best Pract Res Clin Gastroenterol. Best Pract Res Clin Gastroenterol. 2023 Feb;62-63:101826. doi: 10.1016/j.bpg.2023.101826
   PubMed Web of Science ®Google Scholar
• Tosetti C, Savarino E, Benedetto E, et al. Elimination of dietary triggers is successful in treating symptoms of gastroesophageal reflux disease. Dig Dis Sci. 2021 May;66(5):1565–1571. doi: 10.1007/s10620-020-06414-z
   PubMed Web of Science ®Google Scholar
• Zentilin P, Dulbecco P, Bilardi C, et al. Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD). Aliment Pharmacol Ther. 2003;17(3):353–359. doi: 10.1046/j.1365-2036.2003.01422.x
   PubMed Web of Science ®Google Scholar
• Savarino E, Frazzoni M, Marabotto E, et al. A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. Dig Liver Dis. 2020;52(9):966–980. doi: 10.1016/j.dld.2020.04.031
   PubMedGoogle Scholar
• Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol. 2013;10(6):371–380. doi: 10.1038/nrgastro.2013.50
   PubMed Web of Science ®Google Scholar
• Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61(9):1340–1354. doi: 10.1136/gutjnl-2011-301897
   PubMed Web of Science ®Google Scholar
• Ghisa M, Barberio B, Savarino V, et al. The Lyon consensus: does it differ from the previous ones? J Neurogastroenterol Motil. 2020;26(3):311–321. doi: 10.5056/jnm20046
   PubMed Web of Science ®Google Scholar
• Zerbib F, Bredenoord AJ, Fass R, et al. ESNM/ANMS consensus paper: diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021 Apr;33(4):e14075. doi: 10.1111/nmo.14075
   PubMed Web of Science ®Google Scholar
• Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333(17):1106–1110. doi: 10.1056/NEJM199510263331703
   PubMed Web of Science ®Google Scholar
• Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005;2: CD003245.
   Google Scholar
• El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2004;99(10):1877–1883. doi: 10.1111/j.1572-0241.2004.30228.x
   PubMedGoogle Scholar
• Kastelein F, Spaander MC, Steyerberg EW, ProBar Study Group, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clinical Gastroenterology And Hepatology. 2013;11(4):382–388.
   PubMed Web of Science ®Google Scholar
• Richter JE. Ear, nose and throat and respiratory manifestations of gastro-esophageal reflux disease: an increasing conundrum. Eur J Gastroenterol Hepatol. 2004;16(9):837–845. doi: 10.1097/00042737-200409000-00004
   PubMed Web of Science ®Google Scholar
• Vaezi MF, Katzka D, Zerbib F. Extraesophageal symptoms and diseases attributed to GERD: where is the pendulum swinging now? Clin Gastroenterol Hepatol. 2018;16(7):1018–1029. doi: 10.1016/j.cgh.2018.02.001
   PubMed Web of Science ®Google Scholar
• Ghisa M, Della Coletta M, Barbuscio I, et al. Updates in the field of non-esophageal gastroesophageal reflux disorder. Expert Rev Gastroenterol Hepatol. 2019;13(9):827–838. doi: 10.1080/17474124.2019.1645593
   PubMed Web of Science ®Google Scholar
• Roman S, Savarino E, Savarino V, et al. Eosinophilic oesophagitis: from physiopathology to treatment. Dig Liver Dis. 2013;45(11):871–878. doi: 10.1016/j.dld.2013.02.015
   PubMedGoogle Scholar
• de Bortoli N, Penagini R, Savarino E, et al. Eosinophilic esophagitis: Update in diagnosis and management Position Paper By The Italian Society Of Gastroenterology And Gastrointestinal Endoscopy (SIGE). Dig Liver Dis. 2017;49(3):254–260. doi: 10.1016/j.dld.2016.11.012
   PubMedGoogle Scholar
• Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of Helicobacter pylori infection in Italy: the iii working group consensus report 2015. Dig Liver Dis. 2015;47(11):903–912. doi: 10.1016/j.dld.2015.06.010
   PubMedGoogle Scholar
• Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016;2016(6): CD009034. doi: 10.1002/14651858.CD009034.pub2
   PubMedGoogle Scholar
• Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.e14. doi: 10.1053/j.gastro.2016.04.006
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther. 2009;30(8):791–815. doi: 10.1111/j.1365-2036.2009.04105.x
   PubMed Web of Science ®Google Scholar
• Savarino V, Marabotto E, Zentilin P, et al. The appropriate use of proton-pump inhibitors. Minerva Med. 2018;109(5):386–399. doi: 10.23736/S0026-4806.18.05705-1
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004;127(5):1329–1337. doi: 10.1053/j.gastro.2004.08.026
   PubMed Web of Science ®Google Scholar
• Magni A, Agostoni P, Bonezzi C, et al. Management of osteoarthritis: expert opinion on NSAIDs. Pain Ther. 2021;10(2):783–808. doi: 10.1007/s40122-021-00260-1
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006;7(1):79. doi: 10.1186/1471-2474-7-79
   PubMedGoogle Scholar
• Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4(10): CD002296. doi: 10.1002/14651858.CD002296
   Google Scholar
• Savarino V, Dulbecco P, de Bortoli N, et al. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19–24. doi: 10.1016/j.ejim.2016.10.007
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Gatta L, Zullo , A, et al. SIF-AIGO-FIMMG Group; Italian society of pharmacology, the Italian association of hospital gastroenterologists, and the Italian federation of general practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016 Nov 9;14(1):179.
   PubMedGoogle Scholar
• Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger–Ellison syndrome. Expert Opin Pharmacother. 2009;10(7):1145–1157. doi: 10.1517/14656560902887035
   PubMed Web of Science ®Google Scholar
• Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient. Nat Rev Gastroenterol Hepatol. 2015;12(2):98–107. doi: 10.1038/nrgastro.2014.235
   PubMed Web of Science ®Google Scholar
• Alhazzani W, Alenezi F, Jaeschke RZ, et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41(3):693–705. doi: 10.1097/CCM.0b013e3182758734
   PubMed Web of Science ®Google Scholar
• Barkun AN, Bardou M, Pham CQ, et al. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107(4):507–520. quiz 521. doi: 10.1038/ajg.2011.474
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;4: CD001960.
   Google Scholar
• 2019 surveillance of gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (NICE guideline CG184) [Internet]. London: National Institute for Health and Care Excellence (NICE); 2019 Feb 13.
   Google Scholar
• Savarino E, Marabotto E, Zentilin P, et al. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opin Drug Saf. 2018;17(8):785–794. doi: 10.1080/14740338.2018.1497155
   PubMed Web of Science ®Google Scholar
• Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27(3):443–454. doi: 10.1016/j.bpg.2013.06.001
   PubMed Web of Science ®Google Scholar
• Laine L, Ahnen D, McClain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651–668. doi: 10.1046/j.1365-2036.2000.00768.x
   PubMed Web of Science ®Google Scholar
• Savarino V, Marabotto E, Furnari M, et al. Latest insights into the hot question of proton pump inhibitor safety – a narrative review. Dig Liver Dis. 2020;52(8):842–852. doi: 10.1016/j.dld.2020.04.020
   PubMedGoogle Scholar
• Piovani D, Tsantes AG, Schünemann HJ, et al. Meta-analysis: use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression. Aliment Pharmacol Ther. 2023 Mar;57(6):653–665. doi: 10.1111/apt.17360
   PubMed Web of Science ®Google Scholar
• Zhang ML, Fan YX, Meng R, et al. Proton pump inhibitors and cancer risk: an umbrella review and meta-analysis of observational studies. Am J Clin Oncol. 2022 Nov 1;45(11):475–485.
   PubMed Web of Science ®Google Scholar
• Peng TR, Wu TW, Li C-H. Li CH Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2023 Jan;28(1):99–109. doi: 10.1007/s10147-022-02253-2
   PubMed Web of Science ®Google Scholar
• Martin FC, Chenevix-Trench G, Yeomans ND. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther. 2016 Nov;44(9):915–925. doi: 10.1111/apt.13800
   PubMed Web of Science ®Google Scholar
• Shang YS, Zhong PY, Ma Y, et al. Efficacy and safety of proton pump inhibitors in patients with coronary artery diseases receiving oral antiplatelet agents and/or anticoagulants: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2022 Jul 1;80(1):1–12.
   PubMed Web of Science ®Google Scholar
• Salvo EM, Ferko NC, Cash SB, et al. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther. 2021 Jul [Epub 2021 Jun 11];54(2):129–143. doi: 10.1111/apt.16407
   PubMed Web of Science ®Google Scholar
• Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56(4):931–950. doi: 10.1007/s10620-010-1560-3
   PubMed Web of Science ®Google Scholar
• Thompson W, Søndergaard J, Jarbøl DE. Side effects of long‐term proton pump inhibitor use: a review. Haastrup PF, Basic Clin Pharmacol Toxicol. 2018;123(2):114–121. doi: 10.1111/bcpt.13023
   PubMed Web of Science ®Google Scholar
• Johnson DA, Katz PO, Armstrong D, et al. The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and delphi consensus. Drugs. 2017;77(5):547–561. doi: 10.1007/s40265-017-0712-6
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American gastroenterological Association. Gastroenterology. 2017; 152(4):706–715. doi: 10.1053/j.gastro.2017.01.031
   PubMed Web of Science ®Google Scholar
• Eusebi LH, Rabitti S, Artesiani ML, et al. Proton pump inhibitors: risks of long-term use. J Gastroenterol Hepatol. 2017;32(7):1295–1302. doi: 10.1111/jgh.13737
   PubMed Web of Science ®Google Scholar
• Ahrens D, Behrens G, Himmel W, et al. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66(8):767–773. doi: 10.1111/j.1742-1241.2012.02973.x
   PubMed Web of Science ®Google Scholar
• Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236(6):619–632. doi: 10.1111/j.1365-2796.1994.tb00855.x
   PubMed Web of Science ®Google Scholar
• Durand C, Willett KC, Desilets AR. Proton pump inhibitor use in hospitalized patients: is overutilization becoming a problem? Clin Med Insights Gastroenterol. 2012;5:65–76. doi: 10.4137/CGast.S9588
   PubMedGoogle Scholar
• Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016;151(6):1105–1112.e10. doi: 10.1053/j.gastro.2016.08.054
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela GS, Zentilin P, et al. Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. J Hepatol. 1996;25(2):152–157. doi: 10.1016/S0168-8278(96)80067-5
   PubMed Web of Science ®Google Scholar
• Savarino V, Marabotto E, Zentilin P, et al. Esophageal reflux hypersensitivity: non-GERD or still GERD? Dig Liver Dis. 2020;52(12):1413–1420. doi: 10.1016/j.dld.2020.10.003
   PubMedGoogle Scholar
• Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2007;5(2):178–185. quiz 140. doi: 10.1016/j.cgh.2006.09.012
   PubMed Web of Science ®Google Scholar
• Savarino E, Pohl D, Zentilin P, et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut. 2009;58(9):1185–1191. doi: 10.1136/gut.2008.175810
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Frazzoni L, Savarino EV, et al. Functional heartburn overlaps with irritable bowel syndrome more often than GERD. Am J Gastroenterol. 2016;111(12):1711–1717. doi: 10.1038/ajg.2016.432
   PubMed Web of Science ®Google Scholar
• Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut. 2012;61(4):501–506. doi: 10.1136/gutjnl-2011-300798
   PubMed Web of Science ®Google Scholar
• Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–328. doi: 10.1038/ajg.2012.444
   PubMed Web of Science ®Google Scholar
• Lanza FL, Chan FKL, Quigley EMM. Practice parameters committee of the American college of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–738. doi: 10.1038/ajg.2009.115
   PubMed Web of Science ®Google Scholar
• Reeve E, Andrews JM, Wiese MD, et al. Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors. Ann Pharmacother. 2015;49(1):29–38. doi: 10.1177/1060028014558290
   PubMed Web of Science ®Google Scholar
• Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013;66(3):201–202. doi: 10.4212/cjhp.v66i3.1261
   PubMedGoogle Scholar
• Haastrup P, Paulsen MS, Begtrup LM, et al. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014;31(6):625–630. doi: 10.1093/fampra/cmu050
   PubMed Web of Science ®Google Scholar
• Walsh K, Kwan D, Marr P, et al. Deprescribing in a family health team: a study of chronic proton pump inhibitor use. J Prim Health Care. 2016;8(2):164–171. doi: 10.1071/HC15946
   PubMedGoogle Scholar
• Thompson W, Black C, Welch V, et al. Patient values and preferences surrounding proton pump inhibitor use: a scoping review. Patient. 2018 Feb;11(1):17–28. doi: 10.1007/s40271-017-0258-4
   PubMedGoogle Scholar
• Reimer C, Søndergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80–87.e1. doi: 10.1053/j.gastro.2009.03.058
   PubMed Web of Science ®Google Scholar
• Turner JP, Richard C, Lussier MT, et al. Deprescribing conversations: a closer look at prescriber–patient communication. Ther Adv Drug Saf. 2018;9(12):687–698. doi: 10.1177/2042098618804490
   PubMed Web of Science ®Google Scholar
• Smeets HM, De Wit NJ, Delnoij DMJ, et al. Patient attitudes towards and experiences with an intervention programme to reduce chronic acid-suppressing drug intake in primary care. Eur J Gen Pract. 2009;15(4):219–225. doi: 10.3109/13814780903452168
   PubMed Web of Science ®Google Scholar
• Spijker-Huiges A, Winters JC, Meyboom-De Jong B. Patients’ views on dyspepsia and acid suppressant drug therapy in general practice. Eur J Gen Pract. 2006;12(1):10–14. doi: 10.1080/13814780600757120
   PubMedGoogle Scholar
• Reeve E, To J, Hendrix I, et al. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793–807. doi: 10.1007/s40266-013-0106-8
   PubMed Web of Science ®Google Scholar
• Thompson W, Nissen M, Haastrup P, et al. Discussing proton pump inhibitor deprescribing: the views of Danish GPs and older patients. BMC Fam Pract. 2020 Aug 8;21(1):160.
   PubMed Web of Science ®Google Scholar
• Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can Fam Physician. 2017 May;63(5):354–364.
   PubMed Web of Science ®Google Scholar
• Bytzer P. Deprescribing proton pump inhibitors: why, when and how. Med J Aust. 2018;209(10):436–438. doi: 10.5694/mja18.00674
   PubMed Web of Science ®Google Scholar
• Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3(3):3. CD011969. doi: 10.1002/14651858.CD011969.pub2
   Google Scholar
• Bayerdorffer E, Bigard MA, Weiss W, et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol. 2016;16(1):48. doi: 10.1186/s12876-016-0448-x
   PubMedGoogle Scholar
• Bour B, Staub JL, Chousterman M, et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther. 2005;21(7):805–812. doi: 10.1111/j.1365-2036.2005.02413.x
   PubMed Web of Science ®Google Scholar
• Inadomi JM, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003;98(9):1940–1944. doi: 10.1111/j.1572-0241.2003.07665.x
   PubMed Web of Science ®Google Scholar
• Fass R, Inadomi J, Han C, et al. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012;10(3):247–253. doi: 10.1016/j.cgh.2011.11.021
   PubMed Web of Science ®Google Scholar
• Cote GA, Ferreira MR, Rozenberg-Ben-Dror K, et al. Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. Aliment Pharmacol Ther. 2007;25(6):709–714. doi: 10.1111/j.1365-2036.2007.03248.x
   PubMed Web of Science ®Google Scholar
• Tsuzuki T, Okada H, Kawahara Y, et al. Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. World J Gastroenterol. 2011;17(11):1480–1487. doi: 10.3748/wjg.v17.i11.1480
   PubMed Web of Science ®Google Scholar
• Visaggi P, Mariani L, Svizzero FB, et al. Clinical use of mean nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index for the diagnosis of gastro-esophageal reflux disease. Esophagus. 2022 Oct;19(4):525–534. doi: 10.1007/s10388-022-00933-6
   PubMed Web of Science ®Google Scholar
• Yadlapati R, Pandolfino JE. Personalized approach in the work-up and management of gastroesophageal reflux disease. Gastrointest Endosc Clin N Am. 2020 Apr;30(2):227–238. doi: 10.1016/j.giec.2019.12.002
   PubMedGoogle Scholar
• Farrell B, Grant RE, Dilliott D, et al. Lessons learned from using whiteboard videos and YouTube for deprescribing guidelines knowledge mobilization. Int J Pharm Pract. 2022 Nov 4;30(5):441–448.
   PubMed Web of Science ®Google Scholar
• Tarabay RB, Osman MH, Aridi RS, et al. The effect of a patient informative leaflet on chronic use of proton pump inhibitors in a primary care center: a randomized control trial. Hosp Pract. 2022 Oct;50(4):318–325. doi: 10.1080/21548331.2022.2114743
   PubMedGoogle Scholar
• Nguyen-Soenen J, Rat C, Gaultier A, et al. Effectiveness of a multi-faceted intervention to deprescribe proton pump inhibitors in primary care: protocol for a population-based, pragmatic, cluster-randomized controlled trial. BMC Health Serv Res. 2022;22(1):219. doi: 10.1186/s12913-022-07496-3
   PubMed Web of Science ®Google Scholar
• Coyle C, Symonds R, Allan J, et al. Sustained proton pump inhibitor deprescribing among dyspeptic patients in general practice: a return to self-management through a programme of education and alginate rescue therapy. A prospective interventional study. BJGP Open. 2019 Oct 29;3(3):bjgpopen19X101651.
   PubMedGoogle Scholar
• Murie J, Allen J, Simmonds R, et al. Glad you brought it up: a patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice. Qual Prim Care. 2012;20(2):141–148.
   PubMedGoogle Scholar
• Savarino E, Anastasiou F, Labenz J, et al. Holistic management of symptomatic reflux: rising to the challenge of proton pump inhibitor overuse. Br J Gen Pract. 2022 Oct 27;72(724):541–544.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. CG184. London: NICE; 2019. Available from:https://www.nice.org.uk/guidance/cg184
   Google Scholar
• Roman S, Gyawali CP, Savarino E, et al. GERD consensus group. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017 Oct;29(10):1–15. doi: 10.1111/nmo.13067
   PubMed Web of Science ®Google Scholar
• Tack J, Pauwels A, Roman S, et al. ESNM HRM consensus group. European Society for Neurogastroenterology and Motility (ESNM) recommendations for the use of high-resolution manometry of the esophagus. Neurogastroenterol Motil. 2021 May;33(5):e14043. doi: 10.1111/nmo.14043
   PubMed Web of Science ®Google Scholar
• Savarino E, Bredenoord AJ, Fox M, et al. Expert consensus document: advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):665–676. doi: 10.1038/nrgastro.2017.130
   PubMed Web of Science ®Google Scholar
• Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon consensus. Gut. 2018 Jul;67(7):1351–1362. doi: 10.1136/gutjnl-2017-314722
   PubMed Web of Science ®Google Scholar
• Gyawali CP, Rogers B, Frazzoni M, et al. Inter-reviewer variability in interpretation of ph-impedance studies: the wingate consensus. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1976–1978.e1. doi: 10.1016/j.cgh.2020.09.002
   PubMed Web of Science ®Google Scholar
• Rogers B, Rogers B, Frazzoni M, et al. Episode-level reflux characteristics: how experienced reviewers differentiate true reflux from artifact on pH-impedance studies. Neurogastroenterol Motil. 2022 Feb;34(2):e14153. doi: 10.1111/nmo.14153
   PubMed Web of Science ®Google Scholar
• Sifrim D, Roman S, Savarino E, et al. Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world. Gut. 2020 Oct;9(8):gutjnl-2020–322627. doi: 10.1136/gutjnl-2020-322627
   Google Scholar
• Frazzoni M, Frazzoni L, Ribolsi M, et al. Applying Lyon consensus criteria in the work-up of patients with proton pump inhibitory-refractory heartburn. Aliment Pharmacol Ther. 2022 Jun;55(11):1423–1430. doi: 10.1111/apt.16838
   PubMed Web of Science ®Google Scholar
• Frazzoni L, Frazzoni M, De Bortoli N, et al. Application of Lyon consensus criteria for GORD diagnosis: evaluation of conventional and new impedance-pH parameters. Gut. 2022 Jun;71(6):1062–1067. doi: 10.1136/gutjnl-2021-325531
   PubMed Web of Science ®Google Scholar
• Ribolsi M, Frazzoni M, Marabotto E, et al. Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon consensus. Aliment Pharmacol Ther. 2021 Aug;54(4):412–418. doi: 10.1111/apt.16481
   PubMed Web of Science ®Google Scholar
• Ribolsi M, Savarino E, Frazzoni M, et al. Prospective validation of reflux monitoring by impedance-pH in predicting PPI response in typical GERD. Dig Liver Dis. 2023 Jun;55(6):721–726. doi: 10.1016/j.dld.2022.12.004
   PubMedGoogle Scholar
• Rusu RI, Fox MR, Tucker E, et al. Validation of the Lyon classification for GORD diagnosis: acid exposure time assessed by prolonged wireless pH monitoring in healthy controls and patients with erosive oesophagitis. Gut. 2021 Dec;70(12):2230–2237. doi: 10.1136/gutjnl-2020-323798
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Martinucci I, Savarino E, et al. Association between baseline impedance values and response proton pump inhibitors in patients with heartburn. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1082–8.e1. doi: 10.1016/j.cgh.2014.11.035
   PubMed Web of Science ®Google Scholar
• Frazzoni M, Savarino E, de Bortoli N, et al. Analyses of the post-reflux swallow-induced peristaltic wave index and nocturnal baseline impedance parameters increase the diagnostic yield of impedance-pH monitoring of patients with reflux disease. Clin Gastroenterol Hepatol. 2016 Jan;14(1):40–46. doi: 10.1016/j.cgh.2015.06.026
   PubMed Web of Science ®Google Scholar
• Frazzoni M, de Bortoli N, Frazzoni L, et al. Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn. J Gastroenterol. 2017 Apr;52(4):444–451. doi: 10.1007/s00535-016-1226-9
   PubMed Web of Science ®Google Scholar
• Frazzoni M, Frazzoni L, Tolone S, et al. Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn. Am J Gastroenterol. 2018 May;113(5):670–676. doi: 10.1038/s41395-018-0044-5
   PubMed Web of Science ®Google Scholar
• Ribolsi M, Frazzoni M, Marchetti L, et al. Proximal esophageal impedance baseline increases the yield of impedance-pH monitoring for GERD diagnosis and is associated with heartburn response to PPI. Neurogastroenterol Motil. 2023 May 19;35(8):e14612.
   PubMed Web of Science ®Google Scholar
• Gyawali CP, Tutuian R, Zerbib F, et al. Value of pH Impedance monitoring while on twice-daily proton pump inhibitor therapy to identify need for escalation of reflux management. Gastroenterology. 2021 Nov;161(5):1412–1422. doi: 10.1053/j.gastro.2021.07.004
   PubMed Web of Science ®Google Scholar
• Frazzoni M, Frazzoni L, Ribolsi M, et al. On-therapy impedance-pH monitoring can efficiently characterize PPI-refractory GERD and support treatment escalation. Neurogastroenterol Motil. 2023 May;35(5):e14547. doi: 10.1111/nmo.14547
   PubMed Web of Science ®Google Scholar
• Frazzoni M, de Bortoli N, Frazzoni L, et al. The added diagnostic value of postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with on-therapy impedance-pH monitoring. Neurogastroenterol Motil. 2017 Mar;29(3):e12947. doi: 10.1111/nmo.12947
   Web of Science ®Google Scholar
• Yadlapati R, Gyawali CP, Masihi M, et al. Optimal wireless reflux monitoring metrics to predict discontinuation of proton pump inhibitor therapy. Am J Gastroenterol. 2022 Oct 1;117(10):1573–1582. doi: 10.14309/ajg.0000000000001871
   PubMed Web of Science ®Google Scholar
• Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory reflux monitoring guides proton pump inhibitor discontinuation in patients with gastroesophageal reflux symptoms: a clinical trial. Gastroenterology. 2021 Jan;160(1):174–182.e1. doi: 10.1053/j.gastro.2020.09.013
   PubMed Web of Science ®Google Scholar
• Sifrim D, Gyawali CP. Prolonged wireless pH Monitoring or 24-hour catheter-based ph impedance monitoring: who, when, and why? Am J Gastroenterol. 2020 Aug;115(8):1150–1152. doi: 10.14309/ajg.0000000000000648
   PubMed Web of Science ®Google Scholar
• Yadlapati R, Kahrilas PJ, Fox MR, et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©. Neurogastroenterol Motil. 2021 Jan;33(1):e14058. doi: 10.1111/nmo.14058
   PubMed Web of Science ®Google Scholar
• Gyawali CP, Roman S, Bredenoord AJ, et al. Classification of esophageal motor findings in gastro-esophageal reflux disease: conclusions from an international consensus group. Neurogastroenterol Motil. 2017 Dec;29(12):e13104. doi: 10.1111/nmo.13104
   Web of Science ®Google Scholar
• Tolone S, Savarino E, Zaninotto G, et al. High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: a comparison with surgical in vivo evaluation. United Eur Gastroenterol J. 2018 Aug;6(7):981–989. doi: 10.1177/2050640618769160
   PubMed Web of Science ®Google Scholar
• Ribolsi M, Savarino E, Rogers B, et al. High-resolution manometry determinants of refractoriness of reflux symptoms to proton pump inhibitor therapy. J Neurogastroenterol Motil. 2020 Sep 30;26(4):447–454.
   PubMed Web of Science ®Google Scholar
• Rogers B, Samanta S, Ghobadi K, et al. Artificial intelligence automates and augments baseline impedance measurements from pH-impedance studies in gastroesophageal reflux disease. J Gastroenterol. 2021 Jan;56(1):34–41. doi: 10.1007/s00535-020-01743-2
   PubMed Web of Science ®Google Scholar
• Visaggi P, Barberio B, Gregori D, et al. Systematic review with meta-analysis: artificial intelligence in the diagnosis of oesophageal diseases. Aliment Pharmacol Ther. 2022 Mar;55(5):528–540. doi: 10.1111/apt.16778
   PubMed Web of Science ®Google Scholar
• Visaggi P, de Bortoli N, Barberio B, et al. Artificial intelligence in the diagnosis of upper gastrointestinal diseases. J Clin Gastroenterol. 2022 Jan 1;56(1):23–3.
   PubMed Web of Science ®Google Scholar
• Ribolsi M, Luca Guarino MP, Balestrieri P, et al. The results from up-front esophageal testing predict proton pump inhibitor response in patients with chronic cough. Am J Gastroenterol. 2021 Nov 1;116(11):2199–2206.
   PubMed Web of Science ®Google Scholar
• Patel DA, Higginbotham T, Slaughter JC, et al. Development and validation of a mucosal impedance contour analysis system to distinguish esophageal disorders. Gastroenterology. 2019 May;156(6):1617–1626.e1. doi: 10.1053/j.gastro.2019.01.253
   PubMed Web of Science ®Google Scholar
• Savarino E, di Pietro M, Bredenoord AJ, et al. Use of the functional lumen imaging probe in clinical esophagology. Am J Gastroenterol. 2020 Nov;115(11):1786–1796. doi: 10.14309/ajg.0000000000000773
   PubMed Web of Science ®Google Scholar